Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01710371 · ClinicalTrials.gov registry record · Phase 1
Quantitative 18F-AV-133 PET Imaging in Subjects With Diabetes and Healthy Controls
A Phase 1 study, sponsored by Avid Radiopharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT01710371 is a Phase 1 study that has completed, run by Avid Radiopharmaceuticals. The registered enrollment target is 40 participants.
The verdict
NCT01710371, a Phase 1 study, has completed, sponsored by Avid Radiopharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
To evaluate 18F-AV-133 imaging of the pancreas in patients with early type 2 diabetes, late type 2 diabetes, subjects with pre-diabetes and in healthy overweight/obese control subjects. These subjects will also be evaluated for beta-cell function as measured by the insulin and C-peptide response to a challenge with intravenous arginine under basal and glucose enhanced conditions.
Interventions
- DRUG 18F-AV-133
- DRUG 10% Arginine Hydrochloride-R-Gene 10
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2012-12 |
| Est. Completion | 2015-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01710371
The ClinicalTrials.gov registry entry for NCT01710371 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avid Radiopharmaceuticals, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 18F-AV-133 is the first listed.
NCT01710371 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01710371 about?
NCT01710371 is a clinical study titled "Quantitative 18F-AV-133 PET Imaging in Subjects With Diabetes and Healthy Controls". To evaluate 18F-AV-133 imaging of the pancreas in patients with early type 2 diabetes, late type 2 diabetes, subjects with pre-diabetes and in healthy overweight/obese control subjects. These subjects will also be evaluated for beta-cell function as measured by the insulin and C-peptide response to ...
What is the current status of trial NCT01710371?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2012-12. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01710371?
The interventions under investigation include: 18F-AV-133 (DRUG), 10% Arginine Hydrochloride-R-Gene 10 (DRUG).
Who is sponsoring clinical trial NCT01710371?
This trial is sponsored by Avid Radiopharmaceuticals, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.